Name: Latest research reports of Alkem Laboratories Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alkem Laboratories Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alkem Laboratories Ltd.

NSE: ALKEM | BSE: 539523 | ISIN: INE540L01014 | Industry: Pharmaceuticals
| Mid-range Performer

4862.5000 19.00 (0.39%)

NSE Jun 06, 2025 15:31 PM

Volume: 181.8K

Alkem Laboratories Ltd.

14 May 2022

4862.50

0.39%

Alkem Labs (BUY): Q4 revenue in line; margin guidance weak

Buy: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q4 revenue of Rs 24.8bn broadly in line with our estimate; PAT reduced 55% to Rs 1.1bn on account of prior years' tax

Number of FII/FPI investors increased from 524 to 535 in Mar 2025 qtr.